Ichor Biologics

[Available On-Demand]
Ichor Biologics is a New York City based, pre-clinical biotechnology company that has generated a novel platform for the development of antibody-based therapeutics. The Ichor platform is built around a novel antigen-presentation/display system, coupled with an in-silico discovery platform. Ichor has also developed novel immune screening assays, which enable the rapidly profiling of protective immune responses.

Initially, Ichor aims to utilize this platform to accelerate therapeutic development in the infectious disease space, but plans to use it's technology to develop therapeutics in the Immuno-Oncology space. The speed and efficacy of the platform will reduce the costs associated with generating intellectual property (IP) that has been validated through the pre-clinical stage, which will then be leveraged to establish strategic partnerships or licensing agreements with larger biopharma partners.
Company Type:
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
Biologic to treat hantaviruses/ Biologic to treat COVID19
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO
Ichor Biologics